da9d049f.5aa3.4131.a2ff.092c78eed32a
— · cohortA2
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- cohortA2
- subtype
- cohortA2
- age_years
- 50
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- OXIDATIVE_PHOSPHORYLATION+0.510
- MYC_TARGETS_V1+0.470
- PROTEIN_SECRETION+0.380
- FATTY_ACID_METABOLISM+0.340
- REACTIVE_OXYGEN_SPECIES_PATHWAY+0.290
- DNA_REPAIR+0.230
- ADIPOGENESIS+0.210
- MYC_TARGETS_V2+0.210
- UNFOLDED_PROTEIN_RESPONSE+0.210
- NOTCH_SIGNALING+0.190
Top 10 suppressed
- ALLOGRAFT_REJECTION-0.540
- EPITHELIAL_MESENCHYMAL_TRANSITION-0.540
- IL6_JAK_STAT3_SIGNALING-0.520
- INFLAMMATORY_RESPONSE-0.500
- INTERFERON_GAMMA_RESPONSE-0.470
- INTERFERON_ALPHA_RESPONSE-0.450
- ANGIOGENESIS-0.440
- COMPLEMENT-0.400
- IL2_STAT5_SIGNALING-0.400
- KRAS_SIGNALING_UP-0.390
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
7 twins match this tumor's tissue · 3 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | C3L-02961 | — | cohortA2 | 0.958 |
| 2 | ULC1533T_S61 | — | cohortA2 | 0.931 |
| 3 | X08d41e55.6d66.4e03.9dc3.3743f3da0453 | — | cohortA2 | 0.927 |
| 4 | BS_K74PZET7 | Med | Medulloblastoma | 0.895 |
| 5 | 131546 | EPN | EPN Tumor | 0.889 |
| 6 | SRR6013506 | — | cohortA2 | 0.877 |
| 7 | MDT-AP-0566 | Med | Medulloblastoma | 0.868 |
| 8 | DRR168565 | — | — | 0.866 |
| 9 | SRR6013568 | — | cohortA2 | 0.865 |
| 10 | SRR5088889 | — | — | 0.861 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 20 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| OXIDATIVE_PHOSPHORYLATION | 0.510 | Remibrutinib | — uncovered |
| MYC_TARGETS_V1 | 0.470 | Inavolisib | — uncovered |
| PROTEIN_SECRETION | 0.380 | Remibrutinib | — uncovered |
| FATTY_ACID_METABOLISM | 0.340 | Inavolisib | — uncovered |
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 0.290 | Inavolisib | — uncovered |
| DNA_REPAIR | 0.230 | Idelalisib | — uncovered |
| ADIPOGENESIS | 0.210 | Inavolisib | — uncovered |
| MYC_TARGETS_V2 | 0.210 | Idelalisib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.210 | Idelalisib | — uncovered |
| NOTCH_SIGNALING | 0.190 | Inavolisib | — uncovered |
| PEROXISOME | 0.130 | Idelalisib | — uncovered |
| PANCREAS_BETA_CELLS | 0.120 | Cobimetinib | — uncovered |
| XENOBIOTIC_METABOLISM | 0.100 | Inavolisib | — uncovered |
| WNT_BETA_CATENIN_SIGNALING | 0.080 | Inavolisib | — uncovered |
| HEME_METABOLISM | 0.070 | Temsirolimus | — uncovered |
| BILE_ACID_METABOLISM | 0.040 | Inavolisib | — uncovered |
| UV_RESPONSE_DN | 0.040 | Inavolisib | — uncovered |
| PI3K_AKT_MTOR_SIGNALING | 0.030 | Inavolisib | — uncovered |
| TGF_BETA_SIGNALING | 0.010 | Inavolisib | — uncovered |
| UV_RESPONSE_UP | 0.010 | Idelalisib | — uncovered |